Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Nu Skin
NUS
$245M
| $67.9M | 0.06% |
1,776,400
+760,100
| +75% | +$24.4M |
|
|
ELME
352
Elme Communities
ELME
$144M
| $67.8M | 0.06% |
3,055,200
-376,800
| -11% | -$8.39M |
|
353
Idexx Laboratories
IDXX
$45.1B
| $67.1M | 0.06% |
203,180
-147,945
| -42% | -$42.8M |
|
354
Intercontinental Exchange
ICE
$84.8B
| $67M | 0.06% |
731,390
+553,690
| +312% | +$50.7M |
|
|
CZR
355
DELISTED
Caesars Entertainment Corporation
CZR
| $66.7M | 0.06% |
5,498,058
-940,200
| -15% | -$9.5M |
|
356
Thomson Reuters
TRI
$43.8B
| $66.4M | 0.06% |
928,440
+800,499
| +626% | +$57.9M |
|
357
Union Pacific
UNP
$174B
| $66.3M | 0.06% |
392,074
+273,174
| +230% | +$43.8M |
|
358
Angi Inc
ANGI
$176M
| $66.3M | 0.06% |
545,280
-18,600
| -3% | -$1.7M |
|
|
GTY
359
Getty Realty Corp
GTY
$2.01B
| $65.3M | 0.06% |
2,199,312
-294,700
| -12% | -$7.81M |
|
360
Televisa
TV
$1.47B
| $64.8M | 0.06% |
12,370,158
-1,252,900
| -9% | -$6.94M |
|
361
UBS Group
UBS
$176B
| $64M | 0.06% |
5,541,700
-3,876,700
| -41% | -$39.9M |
|
362
CRH
CRH
$65.8B
| $63.7M | 0.06% |
1,857,100
-304,300
| -14% | -$9.39M |
|
|
CBPO
363
DELISTED
China Biologic Products Holdings, Inc.
CBPO
| $63.7M | 0.06% |
623,141
+371,745
| +148% | +$39.8M |
|
364
Malibu Boats
MBUU
$564M
| $63.5M | 0.05% |
1,221,901
-184,992
| -13% | -$7.39M |
|
365
Nomad Foods
NOMD
$1.6B
| $63.4M | 0.05% |
2,957,107
+2,305,207
| +354% | +$48.1M |
|
366
Evertec
EVTC
$1.81B
| $63M | 0.05% |
2,242,587
-117,039
| -5% | -$3.1M |
|
367
Independence Realty Trust
IRT
$3.92B
| $62.7M | 0.05% |
5,459,216
-946,505
| -15% | -$9.44M |
|
368
Rambus
RMBS
$11B
| $62.3M | 0.05% |
4,101,086
-326,600
| -7% | -$4.6M |
|
369
EverQuote
EVER
$856M
| $62.2M | 0.05% |
1,070,023
+81,090
| +8% | +$3.81M |
|
370
Cal-Maine
CALM
$3.82B
| $62.2M | 0.05% |
1,398,007
+401,108
| +40% | +$17.1M |
|
371
Coca-Cola Europacific Partners
CCEP
$47.2B
| $61.7M | 0.05% |
1,632,896
+1,294,522
| +383% | +$50.8M |
|
372
America Movil
AMX
$69.7B
| $61.4M | 0.05% |
4,840,449
+1,138,658
| +31% | +$14.2M |
|
373
Edwards Lifesciences
EW
$53.3B
| $61.2M | 0.05% |
885,400
-328,700
| -27% | -$23.4M |
|
374
Viavi Solutions
VIAV
$10.4B
| $60.9M | 0.05% |
4,779,588
-1,537,600
| -24% | -$18.4M |
|
375
Builders FirstSource
BLDR
$7.77B
| $60.5M | 0.05% |
2,923,519
-1,432,000
| -33% | -$25.9M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.